Aravinthan Vignarajah

Aravinthan Vignarajah

Auto-generated profile, based on publicly available information

Aravinthan Vignarajah

Department of Internal Medicine & Geriatrics, Cleveland Clinic Foundation, Cleveland, OH 44111, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
AVAravinthan Vignarajah
Aravinthan Vignarajah
SKSan Kim
San Kim
MAMoath Albliwi
Moath Albliwi
HAHyunjun Max Ahn
Hyunjun Max Ahn
AIAleksandar Izda
Aleksandar Izda
GSGautam Shah
Gautam Shah
Background: Current anticancer treatments can result in cancer therapy–related cardiac dysfunction (CTRCD). While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated cardioprotective properties, their role in CTRCD has not been previously explored. Methods: This retrospective cohort study utilized the TriNetX research network. Adults aged ≥18 years who had a cancer history and who underwent antineoplastic therapy and developed CTRCD between January 1, 2012 and January 1, 2023 were included. Among patients on guideline‐directed medical therapy for heart failure, 2 groups were identified: GLP‐1 RA users and nonusers. Propensity score matching (1:1) was conducted based on demographics, comorbid conditions, and concurrent medications, yielding a matched sample of 837 patients. Outcomes were assessed over a 1‐year follow‐up period. Results: The study cohort found 4982 patients with CTRCD; 837 received GLP‐1 RA therapy (mean age: 69.0 years; 43.8% female; 70.4% White). Compared with nonusers, those treated with GLP‐1 RAs alongside guideline‐directed medical therapy had significantly lower rates of all‐cause mortality (hazard ratio, 0.57 [95% CI, 0.43–0.77]; P <0.001), acute heart failure exacerbations (hazard ratio, 0.69 [95% CI, 0.56–0.85]; P <0.001), and all‐cause hospitalizations (hazard ratio, 0.83 [95% CI, 0.72–0.96]; P =0.009). While reductions in atrial fibrillation/flutter and ventricular tachycardia were observed, they were not statistically significant. Conclusion: Among patients with CTRCD receiving guideline‐directed medical therapy, GLP‐1 RA use may be linked to better 1‐year survival and improved heart failure–related outcomes.

17 November 2025 in American Heart Journal Plus: Cardiology Research and Practice
Verified
Journal Article
Open access
AVAravinthan Vignarajah
Aravinthan Vignarajah
POPeter Oro
Peter Oro
JDJoseph El Dahdah
Joseph El Dahdah
NVNishanthi Vigneswaramoorthy
Nishanthi Vigneswaramoorthy
AVAmanda R. Vest
Amanda R. Vest
GSGautam Shah
Gautam Shah
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a popular first-line treatment option in managing Type 2 Diabetes Mellitus (T2DM) with cardiovascular co morbidities. Studies have established the benefit of GLP-1 RAs in improving cardiovascular (CV) outcomes in patients with T2DM. However, the impact of GLP-1 RAs on mortality and cardiovascular outcomes in patients with T2DM and Heart failure with reduced ejection fraction (HFrEF) remains uncertain. This retrospective cohort study employed an active-comparator new-user design using the TriNetX Research Network database. Patients aged 18 years or older with T2DM and left ventricular ejection fraction of ≤40 % were identified for inclusion. Patients were classified into two groups: GLP-1 RAs users versus dipeptidyl peptidase 4 inhibitor (DPP4i) users. Propensity score matching (1:1) was conducted based on demographics, body mass index, comorbidities, glycated hemoglobin levels, medications and socioeconomic factors resulting in a matched cohort of 26,196 patients. Outcomes analyzed included all-cause mortality, acute myocardial infarction, cerebrovascular accident, and all-cause hospitalization. The GLP-1 RA user group demonstrated a reduced hazard ratio (HR, 95 % confidence interval) over 5 years compared with the DPP4i user group for all-cause mortality (0.62, 0.59–0.66, P < 0.001), all-cause hospitalization (0.71, 0.69–0.73, P < 0.001), acute myocardial infarction (0.87, 0.82–0.92, P < 0.001), heart failure exacerbation (0.83, 0.81–0.86, P < 0.001) and cerebrovascular accidents (0.85, 0.80–0.92, P < 0.001). In patients with T2DM and HFrEF, GLP-1 RA therapy shows potential beneficial effects in reducing CV events over 5 years compared to control (DPP4i) group.

15 November 2025 in JACC: Clinical Electrophysiology
Verified
Journal Article
Open access
AVAravinthan Vignarajah
Aravinthan Vignarajah
MTMin Choon Tan
Min Choon Tan
TWTanusha Winson
Tanusha Winson
NVNishanthi Vigneswaramoorthy
Nishanthi Vigneswaramoorthy
HMHicham El Masry
Hicham El Masry
JLJustin Z. Lee
Justin Z. Lee

3 January 2025 in medRxiv
Verified
Preprint
Open access
PDF file
AVAravinthan Vignarajah
Aravinthan Vignarajah
SKSan Kim
San Kim
MAMoath Albliwi
Moath Albliwi
HAHyunjun Max Ahn
Hyunjun Max Ahn
AIAleksandar Izda
Aleksandar Izda
GSGautam Shah
Gautam Shah
Background: Anti-cancer therapies currently available can lead to cancer therapy-related cardiac dysfunction (CTRCD). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to exhibit cardioprotective effects but its impact on CTRCD has not been evaluated. Objectives: This study evaluates the impact of GLP-1 RAs on all-cause mortality, hospitalization, and heart failure exacerbation in patients with CTRCD. Methods: This is a retrospective cohort analysis using the TriNetX research network. Patients aged ≥18 years with a history of cancer who received antineoplastic therapies and subsequently developed cancer therapy-related cardiac dysfunction (CTRCD) between January 1, 2012, and January 1, 2023, were included. Patients receiving guideline-directed medical therapy (GDMT) for heart failure were divided into two groups: those using GLP-1 RAs and those not using them. Propensity score matching (1:1) was applied based on demographics, comorbidities, and medications, resulting in a matched cohort of 1,223 patients. Outcomes over a 1-year follow-up were measured. Results: The study cohort found 12,410 patients with CTRCD of which 1,223 had received GLP-1 RA treatment (mean age: 66.4 years; 47.3% female; 65.9% White). Patients receiving GLP-1 RAs in addition to GDMT had a significantly lower risk of acute heart failure exacerbations, all-cause mortality, and all-cause hospitalization (OR: 0.566 [95% CI: 0.48-0.668]; P < 0.001). A clinically significant reduction in atrial fibrillation/flutter and ventricular tachycardia was observed in the GLP-1 RA groups, although did not reach statistical significance. Conclusion: In patients with CTRCD, adding GLP-1 RA therapy to GDMT significantly improves mortality and heart failure outcomes over 1 year.

24 January 2025 in Heart Rhythm
Verified
Journal Article
Closed access
AVAravinthan Vignarajah
Aravinthan Vignarajah
MTMin Choon Tan
Min Choon Tan
NVNishanthi Vigneswaramoorthy
Nishanthi Vigneswaramoorthy
KTKamala Tamirisa
Kamala Tamirisa
LSLuis R. Scott
Luis R. Scott
JLJustin Z. Lee
Justin Z. Lee

9 July 2026 in JACC: Case Reports
Verified
Journal Article
Open access
EGEl-Moatasem Gabr
El-Moatasem Gabr
AVAravinthan Vignarajah
Aravinthan Vignarajah
GSGautam Shah
Gautam Shah
Mitral valve repair (MVr) can alter left ventricular outflow tract (LVOT) geometry and precipitate dynamic LVOT obstruction (LVOTO) in patients with underlying hypertrophic cardiomyopathy (HCM). Cardiac myosin inhibitors are now a Class I recommendation for symptomatic obstructive HCM, yet their role in post-surgical LVOTO remains undefined. A 66-year-old woman with prior MVr developed progressive symptomatic dynamic LVOTO with resting and Valsalva gradients of 33 and 48 mmHg, systolic anterior motion (SAM), and NYHA class II-III symptoms. Mavacamten produced marked gradient reduction to 7 mmHg at rest and with Valsalva, with SAM resolution and symptomatic improvement to NYHA class II. Dose reduction to 2.5 mg led to gradient recurrence; re-escalation to 5 mg restored suppression, suggesting a reproducible dose-dependent effect. Mavacamten effectively reduced dynamic LVOTO despite surgically altered mitral geometry, expanding the therapeutic scope of myosin inhibition to a post-surgical population not well represented in the major trials. Dynamic LVOTO may emerge or progress after mitral valve repair in patients with underlying hypertrophic cardiomyopathy. Mavacamten may provide effective non-surgical suppression of post-repair dynamic LVOTO despite surgically altered mitral geometry.